PER-001 Intravitreal Implant - High Dose

DRUG2 trials

Sponsors

Perfuse Therapeutics, Inc.

Conditions

Diabetic RetinopathyOpen-angle Glaucoma

Phase 1

A Study of PER-001 in Participants With Open-Angle Glaucoma

CompletedNCT05822245

Perfuse Therapeutics, Inc.Open-angle Glaucoma

Start: 2023-05-25End: 2025-04-20Updated: 2026-06-05

Phase 2

A Study of PER-001 in Participants With Diabetic Retinopathy

CompletedNCT06003751

Perfuse Therapeutics, Inc.Diabetic Retinopathy

Start: 2023-08-05End: 2025-12-10Updated: 2026-06-05